Extended release of neuregulin for improved cardiac function
The present invention provides extended release compositions comprising neuregulin for preventing, treating or delaying various diseases or disorders. The present invention also provides methods for preventing, treating or delaying various diseases or disorders by extended release of neuregulin.
1 - 85 . (canceled)
86 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising an osmotic pump and a therapeutically effective amount of neuregulin.
87 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising poly(ethylene glycol) and a therapeutically effective amount of neuregulin.
88 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising a liposome and a therapeutically effective amount of neuregulin.
89 . An extended release composition for preventing, treating or delaying a disease or disorder in a mammal comprising a microsphere and a therapeutically effective amount of neuregulin.
90 . A method for preventing, treating or delaying heart failure in a mammal, the method comprising extended release of neuregulin into a mammal.
91 . The method of claim 90 , wherein the extended release of NRG into a mammal enhances the EF value of the mammal.
92 . The method of claim 91 wherein the EF value of the mammal is enhanced by a percentage selected from the group consisting of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50% and greater than about 60%.
93 . The method of claim 90 , wherein the extended release of NRG into a mammal enhances the FS value of the mammal.
94 . The method of claim 93 wherein the FS value of the mammal is enhanced by a percentage selected from the group consisting of greater than about 20%, greater than about 30%, greater than about 40%, greater than about 50% and greater than about 60%.
95 . The method of claim 90 , wherein the extended release of NRG into a mammal reduces the interior diameter of the left ventricle (LVEDD or LVESD).
96 . The method of claim 95 , wherein the LVEDD value is reduced by a percentage selected from the group consisting of greater than about 2%, greater than about 5%, greater than about 10% and greater than about 15%.
97 . The method of claim 95 , wherein the LVESD value is reduced by a percentage selected from the group consisting of greater than about 2%, greater than about 5%, greater than about 10%, greater than about 15% and greater than about 20%.
98 . The method of claim 90 , wherein the extended release of neuregulin into a mammal induces sustained activation of the ERK signaling pathway in cardiac cells.
99 . The method of claim 90 , wherein the extended release of neuregulin into a mammal induces sustained activation of the AKT signaling pathway in cardiac cells.
100 . The method of claim 90 , herein the extended release of neuregulin into a mammal is accomplished by attaching a polymer to neuregulin.
101 . The method of claim 100 , wherein said polymer is poly(ethylene glycol).
102 . The method of claim 100 , wherein said polymer is a poly(ethylene glycol) derivative.
103 . The method of claim 90 , wherein the extended release of neuregulin into a mammal is accomplished through the use of liposomes.
104 . The method of claim 90 , wherein the extended release of neuregulin into a mammal is accomplished through the use of microspheres.
105 . The method of claim 90 , wherein the neuregulin is selected from the group comprising NRG1, NRG2, NRG3 and NRG4.
106 . The method of claim 90 , wherein the neuregulin comprising the epidermal growth factor-like (EGF-like) domain, wherein the EGF-like domain is encoded by neuregulin 1 gene.
107 . The method of claim 90 , wherein the extended release of neuregulin comprising continuously injection or infusion of neuregulin for 1 min to 24 hours per day.
108 . The method of claim 90 , wherein the extended release of neuregulin including continuously intravenously infusion or injection of neuregulin for 4 or more hours per day.
109 . The method of claim 90 , wherein the extended release of neuregulin including continuously hypodermically infusion or injection of neuregulin for 6 or more hours per day.
110 . A method for reducing a side effect in a mammal subjected to neuregulin treatment, the method comprising extended release of neuregulin into a mammal.
111 . The method of claim 110 , wherein the side effect is gastrointestinal disorder or pericardial effusion.